DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen) for prophylaxis ...
Could the approval lead to new partnership, licensing, or acquisition opportunities that might further influence IONS' valuation?
What is the anticipated market penetration for DAWNZERA™ compared to existing HAE therapies, and how might pricing affect Ionis' profit margins?
How will the FDA approval of DAWNZERA™ impact Ionis Pharmaceuticals' short‑term revenue and earnings guidance?
2 days ago